Welcome to BioSeeker Group!

Triple Analysis: Lymphoma, Cancer Vaccines and Protein Kinase Inhibitors

Additional Information

Published Date Mar 19, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 4901
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Lymphoma, Cancer Vaccines and Protein Kinase Inhibitors in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in Lymphoma and by the two mechanism/target/effect areas of Cancer Vaccines and Protein Kinase Inhibitors.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lymphoma, Cancer Vaccines and Protein Kinase Inhibitors.

    To find out more about Triple Analysis: Lymphoma, Cancer Vaccines and Protein Kinase Inhibitors, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lymphoma, Cancer Vaccines and Protein Kinase Inhibitors is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in Lymphoma and by the two mechanism/target/effect areas of Cancer Vaccines and Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part II: Cancer Vaccines
The cancer vaccine drug report part comprises defined and up to date development strategies for 196 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 137 identified drug targets, organized into 114 drug target strategies, and assesses them in 52 cancer indications.
This part is based on the following publication:
Cancer Vaccines: From First-in-Class to Best-in-Class?

Part III: Protein Kinase Inhibitors
The protein kinase drug report part comprises defined and up to date development strategies for 648 drugs in oncology within the portfolio of 212 companies world-wide, from Ceased to Marketed. The report extensively analyses their 183 identified drug targets, organized into 278 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Lymphoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948
Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

Part II: Cancer Vaccines
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (137 Drug Targets) 32-245
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs (114 Drug Target Strategies and 196 Drugs) 246-262
8 Is First-in-Class the Best-in-Class? 263-386
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 387-413
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414-416
11 Selecting Indications for Cancer Vaccine Drugs (52 Cancer Indications) 417-492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company (114 Companies and 196 Drugs) 493-993
13 Disclaimer 994
Figures: Includes 5 Figures
Tables: Includes 239 Tables
Total Number of Pages: 1,007

Part III: Protein Kinase Inhibitors
5.1 The Scope of this Report 38
6 Consider the Therapeutic Target Among Protein Kinase Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (183 Drug Targets) 42-516
7 Emerging New Products to Established Ones: Drug Target Strategies of Protein Kinase Drugs in Oncology by their Highest Stage of Development (278 Drug Target Strategies and 648 Drugs) 517-945
8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Cancer Drugs by Compound Strategy (8 Compound Strategies) 946-1013
9 Selecting Indication for Protein Kinase Drugs in Oncology (70 Cancer Indications) 1014-1223
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Protein Kinase Drug Pipeline in Oncology by Investigator (212 Investigators and 648 Drugs) 1224-2939
11 Disclaimer 2940
Figures: Includes 8 Figures
Tables: Includes 389 Tables
Total Number of Pages: 2,940

This Report Includes the Following Companies:
4SC
AB Science
Abbott
Abiogen
AC Immune
Acceleron Pharma
ACT Biotech
Adaptimmune
Advaxis
Advenchen
AEgera
AEterna Zentaris
Affimed Therapeutics
Agenus
Aida Pharmaceuticals
Alethia Biotherapeutics
Alfa Wassermann
Alfacell
Allist Pharmaceuticals
Allos Therapeutics
Allostera
AlphaVax
Ambit Biosciences
Amgen
Amphora
Ansaris
Anza Therapeutics
Apogee Biotechnology
Apricus Biosciences
Argos Therapeutics
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
Avila Therapeutics
Bavarian Nordic
Bayer
Bellicum Pharmaceuticals
Benitec
Berkeley Lab
Bio-Path Holdings
BioAxone
Biocon
BioCryst Pharmaceuticals
Biogen Idec
Biolex
Bionovo
BioNTech
BioSante
Biostar
Biotecnol
Biotica Technology
BioVex
Boehringer Ingelheim
Borean Pharma
BreakThrough Therapeutics
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Cambrex
CanBas
Cancer Advances
Cancer Research Technology
Catalyst Biosciences
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Celleron
Celltrion
Center of Molecular Immunology
Cephalon
CerRx
CG Therapeutics
Chroma Therapeutics
Circadian Technologies
Cleveland BioLabs
Clinical Data
CompleGen
Compugen
CoNCERT Pharmaceuticals
Cornerstone Pharmaceuticals
Cosmo Pharmaceuticals
CreaGene
CSL
CureTech
CureVac
Curis
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytokine PharmaSciences
Cytokinetics
Cytopia
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
Dr Reddy’s
Dyax
Dynavax Technologies
Eisai
Elara Pharmaceuticals
Eleos
Eli Lilly
Emergent BioSolutions
Enkam Pharmaceuticals
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Epizyme
Erimos
Etubics
Exelixis
Favrille
Forma Therapeutics
Galapagos
Galena Biopharma
Gemin X Biotechnologies
Genencor
Genentech
Generex
Genmab
GenOdyssee Pharmaceuticals
GenPat77
Genta
Genticel
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlobeImmune
GlycoGenesys
GPC Biotech
Gradalis
Hanmi
Hayashibara
Heat Biologics
Heber Biotec
HemaQuest
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Hutchison China MediTech
Hy BioPharma
Hypha Discovery
Ichor Medical Systems
Idera Pharmaceuticals
IGF Oncology
ImClone Systems
immatics biotechnologies
ImmunoCellular Therapeutics
ImmunoFrontier
ImmunoGen
Immunomedics
Immunotope
Immunovaccine
Incozen Therapeutics
Incyte Corporation
Inex
Inhibiton Therapeutics
Innate Pharma
InNexus Biotechnology
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Intellikine
Intracel
Introgen Therapeutics
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Italfarmaco
Jennerex Biotherapeutics
Jina Pharmaceuticals
Johnson & Johnson
Kadmon
KAEL-GemVax
KAI Pharmaceuticals
KaloBios
Kalypsys
Karus Therapeutics
Keryx Biopharmaceuticals
Kiadis
Kinex
Kirin Pharma
Kissei
KuDOS
Kyowa Hakko Kirin
Leo
Lexicon Pharmaceuticals
LG Life Sciences
Ligand
Lipotek
Lorus Therapeutics
MacroGenics
Mannkind
Marina Biotech
MaxoCore Pharmaceuticals
Meda
MediGene
MedImmune
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Molecular LogiX
MolMed
Mologen
Momotaro-Gene
Myrexis
Nano Terra
Nektar Therapeutics
Nemod Biotherapeutics
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
NexusPharma
NicOx
Nidus Laboratories
NIH
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
NovaLead
Novartis
NovaRx
Novogen
Noxxon
Nycomed Pharma
Oncalis
OncoMune
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Onyvax
Orchestra Therapeutics
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
Pathway Therapeutics
Pepscan Therapeutics
Peptagen
Peregrine Pharmaceuticals
Pfizer
Pharmacyclics
PharmaForm
PharmaGap
PharmaMar
Pharmexa
Philogen
Phoenix Biotechnology
PHusis Therapeutics
Pieris
Piramal
PIramed
Plexxikon
Portola Pharmaceuticals
Proacta
Progenics Pharmaceuticals
ProNAi Therapeutics
Protherics
Provid
QLT
Quantum Pharmaceuticals
Radient Pharmaceuticals
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Reliance Life Sciences
responsif
Rexahn
Rigel
Samtheo Biopharma
Sanofi
Sanofi-Aventis
Santaris Pharma
Sarepta Therapeutics
Sareum
SBI Biotech
SBIO
Scancell
Schering-Plough
Seattle Genetics
Selvita
Semafore Pharmaceuticals
Sentinel Oncology
SGX Pharmaceuticals
Shionogi
Shire
Silence Therapeutics
Sunesis
SuperGen
SuppreMol
Supratek Pharma
Swedish Orphan Biovitrum
Switch Pharma
Symphogen
Synageva BioPharma
Takeda
Tamir Biotechnology
Tapestry Pharmaceuticals
TapImmune
Targa Therapeutics
TargeGen
TauTaTis
TCD Pharma
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Tigris Pharmaceuticals
Titan Pharmaceuticals
ToolGen
TopoTarget
Tragara Pharmaceuticals
Transgene
TransTech Pharma
Trion Pharma
UCB
United Biomedical
Vaccinex
VasGene Therapeutics
Vaxil BioTherapeutics
Vaximm
Vaxon Biotech
Vectura
Velacor Therapeutics
VentiRx Pharmaceuticals
Vernalis
Vertex Pharmaceuticals
Vical
Vion Pharmaceuticals
VioQuest
Viragen
Virionics
ViroMed
Wyeth
XBiotech
Xcovery
Xencor
Yakult Honsha
YM BioSciences
Zenotech
Zensun
Zenyaku Kogyo
Zydus Cadila
A Shortlist of Drugs Included are:
131I-tositumomab
abagovomab
AC-480
ADXS11-001
AE-37
AF-802
afatinib
AGS-003
alemtuzumab
alvocidib
AMG-386
amrubicin hydrochloride
Angiozyme
ANZ-207
apatinib
AR-42
ARQ-197
astuprotimut-r
AT-7519
AT-9283
Auto TAG vaccine
AVX-701
axitinib
AZD-8055
AZD-8931
bafetinib
barasertib
bardoxolone methyl
belagenpumatucel-L
belinostat
bexarotene
BEZ-235
BGT-226
BI-811283
BIBF-1120
BMS-690514
BMS-754807
BMS-777607
bortezomib
bosutinib
BP-GMAX-CD1
brentuximab vedotin
brivanib alaninate
BV-NSCLC-001
Cabozantinib
CAL-101
CB-10-01
CBP-501
CC-223
CDX-1307
cediranib
CG-201
cladribine
CreaVax-PC
crizotinib
CV-9103
CV-9201
CVac
dacomitinib
danusertib
dasatinib
DCVax-prostate
denileukin diftitox
dinaciclib
dovitinib lactate
E-75
elliptinium acetate
emepepimut-S
endoxifen
ENMD-2076
enzastaurin hydrochloride
epirubicin
erlotinib
everolimus
foretinib
fostamatinib disodium
galiximab
gefitinib
GI-4000
GSK-2118436
GSK-2130579A
GV-1001
GVAX
GVX-3322
HBP-347
Her-2/Neu peptides
Hi-8 MEL
HS-110
ibritumomab tiuxetan
IC-83
icrucumab
ICT-107
idronoxil
imatinib mesilate
imMucin
IMO-2055
INCB-028060
inotuzumab ozogamicin
INSM-18
interferon (alpha)
interferon (alpha2b)
interferon (gamma)
interferon alfa-2b
interferon alpha-2b
interleukin-12
irinotecan hydrochloride
ISA-P53-01
JI-101
JX-594
KD032
KX2-391
lapatinib ditosylate
lenvatinib
lestaurtinib
linifanib
linsitinib
LY-2090314
masitinib
MDX-1379
MGCD-265
MGN-1601
midostaurin
mitoxantrone
MK-1775
MKC-1
MLN-8237
MM-111
motesanib diphosphate
MVA-BN Her-2 vaccine
neratinib
nilotinib
NPB-001-056
obinutuzumab
oblimersen sodium
ofatumumab
ON-01910
onartuzumab
OncoVAX
Onyvax-105
OSI-027
OTS-102
p.DOM-WT1-37/p.DOM-WT1-126 DNA
P276-00
panobinostat
pazopanib hydrochloride
PD-0332991
pegdinetanib
perifosine
PHA-848125AC
pixantrone
plitidepsin
poly-ICLC
polyclonal antibody stimulator
ponatinib
pralatrexate
PROSTVAC
PSMA ADC
PX-866
quinacrine
quizartinib dihydrochloride
RAF-265
ramucirumab
razoxane
Reditux
regorafenib
Reximmune-C
rhIFN-alpha
ridaforolimus
rilotumumab
rindopepimut
rintatolimod
rituximab
romidepsin
ruxolitinib
RX-0201-N
S-488410
SCH-900776
SCIB-1
seliciclib
sipuleucel-T
sirolimus
sobuzoxane
sorafenib tosylate
ß-lapachone
SU-6668
sunitinib malate
Survivac
talmapimod
tandutinib
telatinib
temsirolimus
teniposide
terameprocol
TG-4010
thymalfasin
tipapkinogene sovacivec
tivozanib
triciribine phosphate
TroVax
vandetanib
varlitinib
velimogene aliplasmid
vemurafenib
verpasep caltespen
vitespen
volasertib
vosaroxin
VX-001
XL-147
XL-281
XL-413
XL-647
XL-765
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lymphoma, Cancer Vaccines and Protein Kinase Inhibitors.
    To find out more about Triple Analysis: Lymphoma, Cancer Vaccines and Protein Kinase Inhibitors, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lymphoma, Cancer Vaccines and Protein Kinase Inhibitors is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Colorectal Cancer, Cancer Vaccines and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Colorectal Cancer), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Antibodies). Learn More


Triple Analysis: Melanoma, Apoptosis and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Apoptosis) and one compound specific area (Antibodies). Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Lung Cancer, Melanoma and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Melanoma and by the mechanism/target/effect of Cancer Vaccines. Learn More


Triple Analysis: Breast Cancer, Lymphoma and Pancreatic Cancer
This triple analysis focuses on cancer drug development strategies in Breast Cancer, Lymphoma and Pancreatic Cancer. Learn More